Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…
Italy Pierluigi Petrone outlines family-owned Petrone Group’s wide-range of outsourcing services to the pharmaceutical industry, how its international footprint has evolved over time, and his key priorities as president of Italy’s main primary pharma distribution association, ASSORAM. My dream is that Italy, thanks to its infrastructure and location, can become…
Pharma Legal Handbook All legal aspects surrounding the regulatory reforms in the Polish pharma market. Prepared in association with DLA Piper, a leading law firm in Poland, this is an extract from The Pharma Legal Handbook: Poland, available to purchase here for GBP 119. 1. Are there proposals for reform or significant change…
Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
Global UNICEF is forecasting that between 16.8 billion and 20.9 billion COVID-19 vaccine doses will be produced in 2022. The Economist Intelligence Unit highlights the drivers of this incredible demand as the fact that booster shots will be needed to counter new variants; the increased number of countries requesting the Pfizer…
Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it. Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…
Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…
Global Pharmaceutical sales are expected to rise by 4.9 percent in 2022 according to the Economist Intelligence Unit (EIU) with the US continuing to lead the world in pharmaceutical sales numbers. This rise will be driven partly by COVID-19 vaccine sales and the development of other anti-COVID treatments and will also…
Global Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis has announced a major restructuring; this time, too, citing financial motives. The Swiss giant – fifth in the global…
Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…
Italy Bormioli Pharma’s Andrea Lodetti outlines the company’s evolution towards becoming an international leader in the pharma and primary packaging business, COVID-related business impacts, the shift towards localised manufacturing, and the importance of earlier and deeper collaboration between pharma companies and packaging providers. I hope that the cooperation between packaging…
See our Cookie Privacy Policy Here